- Home
- OABI vs GNFT Comparison
OABI vs GNFT Comparison
Compare OABI & GNFT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OABI
- GNFT
- Stock Information
- Founded
- OABI 2012
- GNFT 1999
- Country
- OABI United States
- GNFT France
- Employees
- OABI N/A
- GNFT N/A
- Industry
- OABI Biotechnology: Pharmaceutical Preparations
- GNFT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- OABI Health Care
- GNFT Health Care
- Exchange
- OABI Nasdaq
- GNFT Nasdaq
- Market Cap
- OABI 198.2M
- GNFT 214.5M
- IPO Year
- OABI N/A
- GNFT 2019
- Fundamental
- Price
- OABI $1.66
- GNFT $3.55
- Analyst Decision
- OABI Strong Buy
- GNFT Strong Buy
- Analyst Count
- OABI 3
- GNFT 1
- Target Price
- OABI $7.00
- GNFT $13.00
- AVG Volume (30 Days)
- OABI 1.1M
- GNFT 2.9K
- Earning Date
- OABI 08-07-2025
- GNFT 04-24-2025
- Dividend Yield
- OABI N/A
- GNFT N/A
- EPS Growth
- OABI N/A
- GNFT N/A
- EPS
- OABI N/A
- GNFT 0.03
- Revenue
- OABI $26,744,000.00
- GNFT $73,187,701.00
- Revenue This Year
- OABI N/A
- GNFT $15.98
- Revenue Next Year
- OABI $45.65
- GNFT N/A
- P/E Ratio
- OABI N/A
- GNFT $125.45
- Revenue Growth
- OABI 27.07
- GNFT 105.01
- 52 Week Low
- OABI $1.22
- GNFT $2.55
- 52 Week High
- OABI $4.96
- GNFT $6.42
- Technical
- Relative Strength Index (RSI)
- OABI 53.98
- GNFT 40.25
- Support Level
- OABI $1.55
- GNFT $3.80
- Resistance Level
- OABI $1.73
- GNFT $4.61
- Average True Range (ATR)
- OABI 0.11
- GNFT 0.11
- MACD
- OABI 0.02
- GNFT -0.06
- Stochastic Oscillator
- OABI 68.13
- GNFT 5.59
About OABI OmniAb Inc.
OmniAb Inc offers therapeutic antibody discovery technologies. It focuses on enabling the rapid development of therapeutics by pushing the frontiers of drug discovery technologies. Its technology platform is designed to enable the efficient discovery of high-quality, fully human antibodies for a wide range of diseases. The heart of the OmniAb technology platform is the Biological Intelligence of its proprietary transgenic animals, including OmniRat, OmniMouse, and OmniChicken, that have been genetically modified to generate antibodies with human sequences which are naturally optimized through in vivo affinity maturation.
About GNFT GENFIT S.A.
Genfit SA is a biotechnology company focused on metabolic and inflammatory diseases, with a particular focus on the liver and gastroenterology. The company's research and development activity relies on its expertise in modulating gene expression through nuclear receptors. Genfit utilizes acquisitions, strategic alliances, and licensing agreements in order to fund the further development of its products. It has one segment the research and development of medicines and diagnostic solutions, the marketing of which depends on the success of the clinical development phase.